OncoFirm patent applications: six patent and three trademark filings
By OncoFirm Diagnostics · Last updated October 2026 (first published August 3, 2026)
New York, NY — August 3, 2026. OncoFirm™ Diagnostics Corporation announced that it has filed six patent applications and three trademark applications relating to the diagnostic technologies it is developing. These are applications, not granted patents or registered trademarks, and each remains subject to examination or review by the relevant office.
This page is the record of that announcement, first published on August 3, 2026. It was edited in October 2026 to remove promotional and investor-relations content; the facts announced are unchanged.
What the applications cover
According to the release, the filings are intended to support six areas of the company’s portfolio:
- Advanced fluorescence-enhanced lateral flow diagnostic technologies
- Multi-biomarker cancer detection platforms
- AI-assisted diagnostic interpretation
- Digital handheld diagnostic reader systems
- Intelligent oncology software platforms
- Proprietary assay design and biomarker detection methodologies
These headings describe the subject matter of the applications. They are not statements about the performance of any product. The research-stage work behind them is described on the pages for the fluorescent lateral flow platform and AI-assisted signal interpretation.
Statement from the founder
“Our intellectual property strategy is one of the cornerstones of our business,” said Jonathan Adam Barash, Founder and CEO of OncoFirm™ Diagnostics Corporation. “Filing six patent applications and three trademark applications demonstrates our commitment to building a world-class diagnostics company focused on innovation, scientific excellence, and technologies that have the potential to improve cancer detection worldwide. While this is an important milestone, we believe it is only the beginning.”
What the filings mean for research partners
For universities, cancer centers and companies considering joint grant projects, the practical effect is that OncoFirm’s background intellectual property is documented before joint work begins. That makes it easier to separate what each party brings to a project from what is created together, which technology-transfer offices typically ask to have defined before a collaboration agreement is signed.
The company’s approach is outlined on the intellectual property page; specific terms would be set out in each project agreement. Partners interested in joint applications can start from the collaboration opportunities page. Related reading: our research framework for AI multi-biomarker blood tests and the brief on laboratory information system integration.
About OncoFirm Diagnostics Corporation
OncoFirm Diagnostics Corporation is a research-and-development-stage company based in Port Washington, New York. It is developing a fluorescent lateral flow immunoassay platform for cancer-associated protein biomarkers, a prototype portable digital fluorescence reader and AI-assisted signal interpretation software. Media inquiries can be sent through the contact page.
Forward-looking statements
This press release contains forward-looking statements regarding anticipated research, intellectual property, product development, commercialization activities, regulatory pathways, market opportunities, and future business prospects. Patent applications are subject to examination by the applicable patent offices, and trademark applications remain subject to review and approval by the applicable trademark authorities. Forward-looking statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. OncoFirm Diagnostics Corporation undertakes no obligation to update these statements except as required by applicable law.
Frequently asked questions
Are these granted patents?
No. They are patent applications, which are subject to examination by the applicable patent offices. An application may be granted, amended or refused.
Are the trademarks registered?
The announcement covers three trademark applications. They remain subject to review and approval by the applicable trademark authorities.
Do the filings mean OncoFirm has a product on the market?
No. OncoFirm’s technologies are in research and development, and no OncoFirm product has been cleared, approved or authorized by the U.S. Food and Drug Administration.
Related research and resources
- Intellectual property — how background and project intellectual property are approached.
- About OncoFirm Diagnostics — the company, its stage and its research focus.
- Funding and research collaboration opportunities — ways to join grant projects.
Research and regulatory status
OncoFirm™ technologies described on this site are in research and development. Their performance characteristics have not been established, and no OncoFirm product has been cleared, approved or authorized by the U.S. Food and Drug Administration. Nothing here is medical advice. Reference to a federal agency or funding program does not imply endorsement, funding, sponsorship or affiliation.
